Prostate cancer gene therapy - Corautus Genetics

Drug Profile

Prostate cancer gene therapy - Corautus Genetics

Alternative Names: IL-3 Dual-AD

Latest Information Update: 29 May 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corautus Genetics
  • Developer Corautus Genetics; Immune Response Corporation
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Immunomodulators; Interleukin 3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Prostate cancer

Most Recent Events

  • 29 May 2003 Discontinued - Preclinical for Prostate cancer in USA (Intratumoural)
  • 19 Feb 2003 GenStar Therapeutics Corporation has merged with Vascular Genetics to form Corautus Genetics
  • 17 Feb 2003 Suspended - Preclinical for Prostate cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top